New Clinical Trial Aims to Improve Treatment Outcomes for Early-Stage Cervical Cancer Patients

Researchers at Obstetrics & Gynecology Hospital of Fudan University are conducting a Phase 2 clinical trial to evaluate the efficacy and safety of a novel combination therapy for early-stage cervical cancer patients. The trial involves 20 participants from the USA and combines the antibody Ivonescimab with chemotherapy drugs paclitaxel and cisplatin, followed by a reduced-scale type A hysterectomy. This approach aims to reduce surgical complications and improve quality of life while maintaining survival outcomes.

Key Takeaways:

• The clinical trial, listed on ClinicalTrials.gov, is a Phase 2 study to investigate the safety and efficacy of Ivonescimab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by type A hysterectomy in stage IB2 and IIA1 cervical cancer patients.
• The trial has a total of 20 participants from the USA and aims to evaluate the combination therapy's impact on survival outcomes and quality of life for early-stage cervical cancer patients.
• Cervical cancer ranks fourth globally in both incidence and mortality rates, making early diagnosis and treatment critical.
• The study aims to explore alternative treatment approaches for Stage IB2/IIA1 cervical cancer that ensure survival outcomes while reducing surgical morbidity and improving quality of life.
• Ivonescimab is a novel humanized tetrameric IgG-scFv bispecific antibody targeting PD-1 and VEGF, which has shown promising efficacy and safety in other tumor types, including non-small cell lung cancer, hepatocellular carcinoma, and recurrent glioblastoma.
• The trial's findings may provide novel insights for optimizing treatment paradigms and ensuring survival outcomes while preserving quality of life.

Statistics:

• Cervical cancer ranks fourth globally in both incidence and mortality rates.
• Stage Ib2 and IIA1 cervical cancer patients still require radical hysterectomy with high risks of postoperative complications and significantly impaired quality of life.
• Combined immunotherapy and anti-angiogenic therapy have demonstrated favorable antitumor efficacy and manageable safety profiles across multiple tumor types.
• Ivonescimab has shown promising efficacy and safety in advanced non-small cell lung cancer, hepatocellular carcinoma, and recurrent glioblastoma.

Sources:

• ClinicalTrials.gov
• NCCN guidelines
• obstetrics & Gynecology Hospital of Fudan University